Welcome!

News Feed Item

Entest BioMedical Inc. Recruits Salk Institute Researcher to Lead Cancer Stem Cell Program for Treating Feline Leukemia and Canine Cancer

SAN DIEGO, CA -- (Marketwired) -- 07/16/14 -- Entest BioMedical Inc. (PINKSHEETS: ENTB)

  • Dr. Christine Ichim to assist in the development of the Company's canine immunotherapy for the treatment of cancer
  • Dr. Ichim has done research on cancer stem cells for more than 14 years

Entest BioMedical Inc. (PINKSHEETS: ENTB) announced today that Dr. Christine Ichim has joined the Company as Its Director of Research. Dr. Ichim was previously with the Salk Institute where she conducted research in the areas of cancer and stem cell division, cell senescence and aging.

While at the University of Toronto, Dr. Ichim began developing research for the treatment of feline leukemia. Dr. Ichim has published her research in peer reviewed journals on immunological therapies for treating cancer. David Koos, Chairman & CEO of Entest BioMedical Inc. noted, "Dr. Ichim has a unique approach to treating leukemia and cancer. She is focused on cell senescence of cancer stem cells. This approach involves forcing cells that would normally become cancerous into a state of maturation where they no longer have the capacity to grow. Cancer cells typically have the ability to expand leading to life threatening conditions such as lung cancer. In this cell senescence approach, these cancer cells are no longer capable of expansion, thus rendering these cells harmless."

Dr. Ichim stated, "I am extremely excited about having the opportunity to apply my knowledge of cancer stem cells to treating leukemia in cats and cancer in dogs. While I was conducting research at the University of Toronto, I developed a model of treating cancer through forcing senescence in cancer stem cells. The next step is to develop animal therapies utilizing this model in veterinary treatments."

A spokesperson for the Company noted that it has spent an extensive period of time evaluating the most effective way to move forward in developing veterinary therapeutics. The Company believes that Dr. Ichim will be instrumental in this endeavor.

DISCLAIMER:
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

About Entest BioMedical Inc.:
Entest BioMedical Inc. (PINKSHEETS: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The Company is currently focused on developing therapies for treating feline leukemia and canine cancer.

About Christine Ichim, PhD:
Dr. Christine Ichim has 20 years of experience in immunology and cancer biology. Dr. Ichim obtained a PhD from the University of Toronto, in the Department of Medical Biophysics. She completed a Master of Science under the tutelage of Dr. Norman Iscove, where she studied the molecular biology of the leukemia stem cell. She completed a PhD focused on a novel oncogene that she identified to control leukemia stem cells. Dr. Ichim completed postdoctoral training at the Salk Institute for Biological Studies, where she conducted research on DNA biology relevant to cell division. This work was funded by the Canadian Institutes of Health Research (CIHR). She has numerous peer reviewed articles including:

The orphan nuclear receptor Ear-2 (Nr2f6) is a novel negative regulator of T cell development.
http://www.ncbi.nlm.nih.gov/pubmed/24096122

Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy.
http://www.ncbi.nlm.nih.gov/pubmed/15698481

Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
http://www.ncbi.nlm.nih.gov/pubmed/24598782

Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy.
http://www.ncbi.nlm.nih.gov/pubmed/21637284

First among equals: the cancer cell hierarchy.
http://www.ncbi.nlm.nih.gov/pubmed/17071472

Contact Entest BioMedical Inc.

David R. Koos
Chairman & CEO

619.702.1404 Direct
619.330.2328 Fax
Email Contact
www.EntestBio.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
Data-as-a-Service is the complete package for the transformation of raw data into meaningful data assets and the delivery of those data assets. In her session at 18th Cloud Expo, Lakshmi Randall, an industry expert, analyst and strategist, will address: What is DaaS (Data-as-a-Service)? Challenges addressed by DaaS Vendors that are enabling DaaS Architecture options for DaaS
One of the bewildering things about DevOps is integrating the massive toolchain including the dozens of new tools that seem to crop up every year. Part of DevOps is Continuous Delivery and having a complex toolchain can add additional integration and setup to your developer environment. In his session at @DevOpsSummit at 18th Cloud Expo, Miko Matsumura, Chief Marketing Officer of Gradle Inc., will discuss which tools to use in a developer stack, how to provision the toolchain to minimize onboa...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, will give users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion w...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
SYS-CON Events announced today that FalconStor Software® Inc., a 15-year innovator of software-defined storage solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. FalconStor Software®, Inc. (NASDAQ: FALC) is a leading software-defined storage company offering a converged, hardware-agnostic, software-defined storage and data services platform. Its flagship solution FreeStor®, utilizes a horizonta...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
SYS-CON Events announced today that (ISC)²® (“ISC-squared”) will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Two leading non-profits focused on cloud and information security, (ISC)² and Cloud Security Alliance (CSA), developed the Certified Cloud Security Professional (CCSP) certification to address the increased demand for cloud security expertise due to rapid growth in cloud. Recently named “The Next...
The Art of DevOps provides a fun overview to help teams understand DevOps. Written in the style of the famous 6th century Chinese manuscript “The Art of War,” this eBook describes DevOps in the form of a mission to continuously deliver assets to the operational battlegrounds safely, securely, and quickly. It’s a fun read with valuable insights.
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
The Quantified Economy represents the total global addressable market (TAM) for IoT that, according to a recent IDC report, will grow to an unprecedented $1.3 trillion by 2019. With this the third wave of the Internet-global proliferation of connected devices, appliances and sensors is poised to take off in 2016. In his session at @ThingsExpo, David McLauchlan, CEO and co-founder of Buddy Platform, will discuss how the ability to access and analyze the massive volume of streaming data from mil...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.